Published in J Neurol on July 05, 2005
A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry (2006) 1.39
Morphological differences in Parkinson's disease with and without rest tremor. J Neurol (2009) 1.12
Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI. PLoS One (2009) 1.12
Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis (2012) 1.12
Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol (2008) 1.05
The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes. Semin Neurol (2014) 0.90
Whole-brain proton MR spectroscopic imaging in Parkinson's disease. J Neuroimaging (2012) 0.89
Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. Neurobiol Aging (2011) 0.89
Neuroimaging and cognition in Parkinson's disease dementia. Brain Pathol (2010) 0.82
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. Neuroimage (2013) 0.82
Magnetic resonance morphometry of the loss of gray matter volume in Parkinson's disease patients. Neural Regen Res (2013) 0.81
Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques. J Alzheimers Dis Parkinsonism (2014) 0.80
Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's disease. J Neurol (2016) 0.78
Mild cognitive impairment in Parkinson's disease: a review of current concepts. Neurol Res Int (2013) 0.78
MRI correlates of Parkinson's disease progression: a voxel based morphometry study. Parkinsons Dis (2015) 0.78
Differential diagnosis tool for parkinsonian syndrome using multiple structural brain measures. Comput Math Methods Med (2013) 0.77
An update on brain imaging in parkinsonian dementia. Imaging Med (2012) 0.77
Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere. Brain Behav (2016) 0.76
Longitudinal changes in task-evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment. Front Neurosci (2014) 0.76
Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson's disease. Brain Res (2013) 0.75
Structural Imaging and Parkinson's Disease: Moving Toward Quantitative Markers of Disease Progression. J Parkinsons Dis (2016) 0.75
Parkinson disease: an update. Neurologist (2004) 0.75
Tracking Parkinson's Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease. PLoS One (2015) 0.75
Gray matter atrophy in patients with Parkinson's disease and those with mild cognitive impairment: a voxel-based morphometry study. Int J Clin Exp Med (2015) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage (2001) 19.86
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci (2003) 7.26
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol (2003) 4.76
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology (1990) 4.41
Cognitive deficits in Parkinson's disease. J Neurol (1997) 2.49
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 2.47
Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry (2002) 2.41
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl (1993) 2.27
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17
Pathoanatomy of Parkinson's disease. J Neurol (2000) 2.16
Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain (2004) 2.06
Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand (1976) 1.87
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain (2002) 1.85
A voxel-based morphometric study to determine individual differences in gray matter density associated with age and cognitive change over time. Cereb Cortex (2004) 1.76
A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol (1992) 1.59
Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neurol (1989) 1.54
Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord (2002) 1.52
Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. J Nucl Med (2002) 1.48
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord (2005) 1.41
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (2000) 1.41
Parkinson's disease is associated with hippocampal atrophy. Mov Disord (2003) 1.37
Frequency of dementia in Parkinson disease. Arch Neurol (1996) 1.30
Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol (2005) 1.18
Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol (2002) 1.17
Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology (2001) 1.16
Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology (2003) 1.12
Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. J Neural Transm (Vienna) (2001) 1.03
The locus ceruleus and dementia in Parkinson's disease. Neurology (1993) 1.01
Amygdala pathology in Parkinson's disease. Acta Neuropathol (1994) 0.99
Cognitive and motor functioning in Parkinson disease: subjects with and without questionable dementia. Arch Neurol (1998) 0.96
Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson's disease. J Neurol Sci (2001) 0.91
Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J Neural Transm (Vienna) (2003) 0.87
Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse (2003) 0.85
Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT. J Neural Transm (Vienna) (2000) 0.82
'Lewy body disease': clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg (1995) 0.80
Brain perfusion imaging in Parkinson's disease and Alzheimer's disease demonstrated by three-dimensional surface display with 123I-iodoamphetamine. Dementia (1994) 0.79
Cortical Lewy body disease. J Neurol Neurosurg Psychiatry (2004) 0.76
Cerebral blood flow and dementia in Parkinson's disease. J Geriatr Psychiatry Neurol (1992) 0.75
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol (2006) 4.72
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. Ann Neurol (2015) 2.71
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord (2010) 2.34
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
Good outcome in patients with normal-pressure hydrocephalus and factors indicating poor prognosis. J Neurosurg (2005) 2.18
Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol (2009) 1.96
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
Brain effects of cognitive remediation therapy in schizophrenia: a structural and functional neuroimaging study. Biol Psychiatry (2013) 1.95
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 1.94
Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol (2011) 1.91
Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord (2009) 1.90
Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiol Aging (2010) 1.87
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep (2012) 1.68
A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord (2008) 1.63
Impact of the COMT Val108/158 Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage (2007) 1.63
Mild cognitive impairment after lacunar infarction: voxel-based morphometry and neuropsychological assessment. Cerebrovasc Dis (2007) 1.57
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol (2010) 1.57
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord (2009) 1.54
Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiol Aging (2007) 1.53
Rapidly progressive diffuse Lewy body disease. Mov Disord (2011) 1.52
Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. Sleep (2008) 1.49
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord (2006) 1.49
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol (2010) 1.41
Cognitive dysfunction and dementia in Parkinson disease. Mov Disord (2007) 1.39
Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. Neuroimage (2003) 1.36
Clinical overview of the synucleinopathies. Mov Disord (2003) 1.36
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol (2010) 1.34
A cross-sectional and follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J Psychiatr Res (2008) 1.31
Brain connectivity during resting state and subsequent working memory task predicts behavioural performance. Cortex (2011) 1.26
Modulation of large-scale brain networks by transcranial direct current stimulation evidenced by resting-state functional MRI. Brain Stimul (2011) 1.25
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry (2007) 1.24
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol (2006) 1.23
Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp (2011) 1.23
Alterations of the salience network in obesity: a resting-state fMRI study. Hum Brain Mapp (2012) 1.23
The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord (2014) 1.21
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Cortical folding abnormalities in schizophrenia patients with resistant auditory hallucinations. Neuroimage (2007) 1.20
Hippocampal head atrophy after traumatic brain injury. Neuropsychologia (2005) 1.20
Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol (2005) 1.18
Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis (2010) 1.18
Repetitive transcranial magnetic stimulation effects on brain function and cognition among elders with memory dysfunction. A randomized sham-controlled study. Cereb Cortex (2005) 1.15
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease. Eur J Neurosci (2009) 1.14
Decreased cerebral activation during CPT performance: structural and functional deficits in schizophrenic patients. Neuroimage (2004) 1.13
Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord (2004) 1.12
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol (2009) 1.12
Health-related quality of life in multiple system atrophy. Mov Disord (2006) 1.11
A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson's disease. Ann Neurol (2004) 1.11
Mental slowness and executive dysfunctions in patients with metabolic syndrome. Neurosci Lett (2009) 1.09
Neuroanatomical substrate of visuospatial and visuoperceptual impairment in Parkinson's disease. Mov Disord (2009) 1.09
Neural bases of different cognitive strategies for facial affect processing in schizophrenia. Schizophr Res (2008) 1.09
Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders. Neuroimage (2013) 1.08
Transient arrest of psychogenic tremor induced by contralateral ballistic movements. Neurosci Lett (2004) 1.08
Amygdalar atrophy in panic disorder patients detected by volumetric magnetic resonance imaging. Neuroimage (2003) 1.08
Correlations of thalamic reductions with verbal fluency impairment in those born prematurely. Neuroreport (2006) 1.08
Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J Alzheimers Dis (2011) 1.08
Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. J Hepatol (2010) 1.08
Cortical thinning is associated with disease stages and dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry (2013) 1.07
Premotor signs and symptoms of multiple system atrophy. Lancet Neurol (2012) 1.06
Dopaminergic modulation of the default mode network in Parkinson's disease. Eur Neuropsychopharmacol (2010) 1.06
Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations. Ann Neurol (2004) 1.06
Decreased regional brain volume and cognitive impairment in preterm children at low risk. Pediatrics (2009) 1.06
Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol (2008) 1.05
Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease. J Neurol Sci (2011) 1.05
Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord (2002) 1.04
Hippocampal gray matter reduction associates with memory deficits in adolescents with history of prematurity. Neuroimage (2004) 1.03
Usefulness of the SINBAR electromyographic montage to detect the motor and vocal manifestations occurring in REM sleep behavior disorder. Sleep Med (2011) 1.03
Functional brain networks and cognitive deficits in Parkinson's disease. Hum Brain Mapp (2014) 1.03
Corpus callosum and prefrontal functions in adolescents with history of very preterm birth. Neuropsychologia (2007) 1.03